25 May 2013
Keywords: roche/genentech, avastin, shows, efficacy, third, cancer, breast
Article | 25 April 2005
An interim analysis of a Phase III study of Swiss drugmaker Roche and its US affiliate Genentech's cancer drug Avastin ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 April 2005
11 April 2005
24 May 2013
© 2013 thepharmaletter.com